Table 5.
Doses of mercaptopurine and methotrexate administered at the second and last maintenance cycles (n=185)
| Second cycle |
Last cycle |
|||
|---|---|---|---|---|
| No. of patients (%) | Median dose (mg/m2/day) | No. of patients (%) | Median dose (mg/m2/day) | |
| MP dose (mg/m2/day) | ||||
| MP < 12.5 | 38 (20.5) | 7.8 | 51 (27.6) | 7 |
| 12.5 ≤ MP < 25 | 58 (31.4) | 17.9 | 41 (22.2) | 17.4 |
| 25 ≤ MP < 37.5 | 37 (20) | 27.8 | 48 (25.9) | 31.3 |
| 37.5 ≤ MP < 50 | 41 (22.2) | 41.7 | 24 (13) | 42.7 |
| MP ≥ 50 | 5 (2.7) | 52.1 | 14 (7.6) | 55.7 |
| Total patients | 179a) | 22.8 | 178b) | 23.5 |
| Methotrexate dose (mg/m2/wk) | ||||
| MTX < 5 | 38 (20.5) | 3.3 | 29 (15.7) | 7 |
| 5 ≤ MTX < 10 | 49 (26.5) | 7.9 | 32 (17.3) | 17.4 |
| 10 ≤ MTX < 15 | 42 (22.7) | 11.8 | 51 (27.6) | 31.3 |
| 15 ≤ MTX < 20 | 46 (24.9) | 17.7 | 39 (21.1) | 42.7 |
| MTX ≥ 20 | 4 (2.2) | 21.3 | 25 (13.5) | 55.7 |
| Total patients | 179a) | 10 | 176c) | 13 |
MP, mercaptopurine; MTX, methotrexate.
a)
Data was not available in six patients,
b)
Data was not available in seven patients,
c)
Data was not available in nine patients.